Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial.
Li-Nong JiXiaozhen JiangQingshun HaoZhifeng ChengKun WangShuguang PangMeiying LiuYushan GuoXiaowen ChenXiuhai SuTao NingJie LiuFang BianYulan LiZhinong ZhangWeihong SongJingfang SunPublished in: Diabetes, obesity & metabolism (2023)
Janagliflozin 25 mg and 50 mg monotherapy once-daily effectively improved glycaemic control, reduced body weight and blood pressure, improved HDL cholesterol and insulin sensitivity, and was generally well tolerated.
Keyphrases
- double blind
- placebo controlled
- body weight
- physical activity
- clinical trial
- blood pressure
- open label
- phase iii
- combination therapy
- study protocol
- phase ii
- type diabetes
- phase ii study
- high intensity
- weight loss
- heart rate
- randomized controlled trial
- hypertensive patients
- low density lipoprotein
- resistance training
- metabolic syndrome
- blood glucose
- body composition
- insulin resistance
- adipose tissue